Skip to content

A Comparison of Blood Angiostatin levels in Healthy Controls vs. COVID-19 patients as a Predictor of COVID-19 Progression

Lung Injury | Healthy Control | Blood Sample | Blood Clotting | COVID-19

COVID-19 has overwhelmed health systems around the world. A molecule within blood that may contribute to COVID-19 progression is a protein called angiostatin. Angiostatin under healthy conditions maintains blood vessels in a normal state. However, it can be overproduced during inflammation and COVID-19 may increase its levels predisposing some people to severe disease. In this study, we aim to determine whether angiostatin is elevated in the blood of COVID-19 patients vs. non-infected individuals. If so, blood angiostatin levels could be used as an indicator of COVID-19 progression, as well as a new drug target to decrease COVID-19 severity. Therefore, we are seeking COVID-19-negative participants to serve as control group within our study.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    35 to 90

Participation Criteria

Inclusion Criteria:
- males and females
- ages 30 - 90
Exclusion Criteria:
- Covid-19 positive individuals

- Individuals previously having tested Covid-19 positive and now recovered

- Individuals with cold/flu-like symptoms

- Individuals within 6 months of a heart attack, stroke, or venous thromboembolic event

- Individuals with active cancer

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Aleksandra Franczak

[email protected]
null
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00100563